Division of Tumor Virology, German Cancer Research Center, and Cancer Virotherapy Unit, French National Institute of Health and Medical Research, Im Neuenheimer Feld 242, D-69120 Heidelberg, Germany.
Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):185-95. doi: 10.1016/j.cytogfr.2010.02.011. Epub 2010 Mar 7.
The experimental infectivity and excellent tolerance of some rodent autonomous parvoviruses in humans, together with their oncosuppressive effects in preclinical models, speak for the inclusion of these agents in the arsenal of oncolytic viruses under consideration for cancer therapy. In particular, wild-type parvovirus H-1PV can achieve a complete cure of various tumors in animal models and kill tumor cells that resist conventional anticancer treatments. There is growing evidence that H-1PV oncosuppression involves an immune component in addition to the direct viral oncolytic effect. This article summarizes the recent assessment of H-1PV antineoplastic activity in glioma, pancreatic ductal adenocarcinoma, and non-Hodgkin lymphoma models, laying the foundation for the present launch of a first phase I/IIa clinical trial on glioma patients.
一些啮齿动物自主细小病毒在人类中的实验感染性和良好耐受性，以及它们在临床前模型中的抗肿瘤作用，表明这些因子应该被包含在用于癌症治疗的溶瘤病毒武器库中。特别是，野生型细小病毒 H-1PV 可以在动物模型中完全治愈各种肿瘤，并杀死抵抗传统抗癌治疗的肿瘤细胞。越来越多的证据表明，H-1PV 的抗肿瘤抑制作用除了直接的病毒溶瘤作用外，还涉及免疫成分。本文总结了 H-1PV 在神经胶质瘤、胰腺导管腺癌和非霍奇金淋巴瘤模型中的抗肿瘤活性的最新评估，为目前针对神经胶质瘤患者的 I/IIa 期临床试验奠定了基础。
